Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Exiqon A/S - Exiqon A/S completes litigation against Santaris Pharma a/s

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2011 | 08:20pm CEST
Exiqon A/S
Company Announcement
Exiqon A/S completes litigation against Santaris Pharma a/s

Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that the company has completed its litigation against Santaris Pharma a/s.

In 2010, Exiqon initiated arbitration proceedings to defend its business against Santaris Pharma.

Exiqon’s product offering includes LNA™ amidites and LNA™ oligonucleotides for the research and development of pharmaceutical products. Exiqon has the exclusive right to supply such products except for use in the research and development of pharmaceutical products containing LNA™ as the active ingredient. Today’s decision by the arbitration court establishes Exiqon’s non-exclusive right to supply these products also for the research and development of pharmaceutical products containing LNA™ as the active ingredient. Santaris Pharma’s request that Exiqon should be prevented from supplying LNA™ products for such use was dismissed.

Following today’s decision, it is clear that both Exiqon and Santaris Pharma may supply LNA™ products for the research and development of pharmaceutical products containing LNA™ as the active ingredient.

In a comment, President and CEO of Exiqon, Lars Kongsbak said: “Exiqon is committed to provide best in class products for the detection of nucleic acids using our LNA™ technology. This has allowed us to become a leader in our markets, and serves as the foundation for Exiqon’s commitment to develop, and help propel the development of, novel molecular diagnostic products, including companion diagnostics, for which we provide easy access to our proprietary technologies through licensing. Proceedings against Santaris Pharma were an unfortunate, but necessary, step towards realizing our business goals.”

Exiqon had requested that Santaris Pharma be ordered to pay damages. However, the arbitration court did not find grounds for damages.

During proceedings, Santaris Pharma submitted a counter claim against Exiqon for damages in the amount of DKK 100 million. This claim was dismissed on substantive grounds.

The arbitration court also decided on the distribution of the costs of proceedings. Santaris Pharma was awarded partial costs of DKK 2 million payable by Exiqon within 14 days.

Exiqon expect today’s decision to impact its full year EBITDA, for which guidance has been provided exclusive of one-time items, with approximately DKK -10 million.

Additional information
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full press release in the attached PDF or at www.exiqon.com/investor/portal.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
06:52p VODAFONE : ‘Security hole’ could open access to home computers
06:52p VODAFONE : Game of Phones
06:52p GOLDMAN SACHS : Setback for Super Fund
06:52p SHUI ON LAND : to Realise Significant Hidden Value of Chongqing Tiandi Project
06:52p COMMONWEALTH SECRETARIAT : East African youth entrepreneur summit closes with pitch to governments
06:52p ZON OPTIMUS SGPS : 26-05-17 - NOS informs on 1Q17 Consolidated Management Report
06:52p INTEL : Final Tabulation Report
06:52p SOUTHERN : Univ. of Tennessee student realizes power of co-op program
06:52p ASIA PACIFIC 3D DISPLAY MARKET 2016-2022 : 3D Display Market is Majorly Driven by the 3D TVs - Research and Markets
06:51p Former Massey House for sale
Latest news
Advertisement
Hot News 
-4.92%SUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
-4.04%BA and Iberia plan third-party booking surcharge, Amadeus shares hit
8.47%SPIRAX SARCO ENGINEERING : Sarco to buy thermal tech firm Chromalox for $415 million
1.40%SAFRAN : investor TCI says reduced offer for Zodiac still too high
2.28%ELECTRA PRIVATE EQUITY : Epiris to keep focus on UK assets after Electra split
Most Read News
11:12a TSX slightly lower, gold miners up with bullion
12:07p Legal & General, Aviva plan Ireland moves post-Brexit
06:58a EXCLUSIVE : Fidelity may back climate resolutions, a milestone for activists
12:16aDJNEWS HIGHLIGHTS : Top Energy News of the Day
12:15a VOLKSWAGEN : California says VW clean car spending plan has shortcomings
Most recommended articles
05/22 NOBLE : shares tumble after S&P ratings downgrade
12:50pDJLONDON MARKETS : FTSE 100 Notches A Record, As Pound Falls Below $1.28
12:43p Some investors bet Brazil has further room to fall
12:35p Oil, banks trip up European shares
12:17p BA and Iberia plan third-party booking surcharge, Amadeus shares hit